GlassScriptPhysician profile
James Neiner
NPI 1619170024
$3,906.49
in general payments reported to CMS, 2019-2025
21 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what 75% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $37.60 · 2021: $53.49 · 2022: $56.98 · 2023: $1,053 · 2024: $1,639 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,554 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,553.79 |
| Education | $204.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,184.15 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $310.92 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $298.98 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $291.03 | 2023-2024 | Sotyktu |
| Organon LLC | $214.35 | 2025 | Vtama, Nexplanon |
| Janssen Biotech, INC. | $213.85 | 2023-2024 | Tremfya |
| Galderma Laboratories, L.P. | $187.16 | 2023-2025 | Aklief, Oracea, Twyneo |
| Dermavant Sciences, INC. | $174.04 | 2023-2024 | Vtama |
| Incyte Corporation | $168.88 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $127.96 | 2023-2025 | |
| Kerecis Limited | $118.60 | 2022-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Genzyme Corporation | $105.63 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $100.55 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $99.59 | 2023-2025 | Ilumya |
| Revance Therapeutics, INC. | $84.52 | 2025 | Daxxify |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $70.79 | 2023-2025 | Bimzelx |
| Organogenesis INC. | $53.12 | 2023-2025 | Puraply, Via Matrix |
| Leo Pharma INC. | $44.97 | 2024 | Adbry |
| Botanix Sb INC | $21.82 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.74 | 2024 | Jublia |
| Journey Medical Corporation | $15.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Neiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.